Abstract
Chloroquine (CQ) and hydroxychloroquine (HCQ) are used in the treatment of malaria and various connective tissue diseases (CTD). They have been associated with muscle toxicity, mostly described as a proximal myopathy with evidence of lysosomal dysfunction on muscle biopsy. As patients with CTD may have muscle weakness due to myositis or steroid myopathy, the diagnosis can be missed or delayed. In this retrospective study, we aimed to define the clinical phenotype, laboratory features and treatment outcomes of CQ/HCQ-myopathy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
